Embed Size (px)
Citation preview
NOVeMBeR 12, 2013: GeNeRAL PROGRAMNOVeMBeR 13, 2013: LiFe SCieNCe SPeCiAL
– Towards a harmonized iP world? –an UPdaTe on The ever FasTer Changing
iP laws in eUroPe and The Us
– 知財制度の統一化にむけて –欧州および米国における知的財産法の最新情報
ACADEMY HILLS • アカデミーヒルズROPPONGI HILLS MORI TOWER 49F • 六本木ヒルズ森タワー49階
www.cppc.jp
greetings ご挨拶
conference venue 会場ご案内
欧州では、EU全域における欧州単一特許と統一特許裁判所の導入にむけた最終段階に入っている一方で、現行制度の下の特許法のそれぞれの部分においても、近年著しい変化が見られています。本セミナーでは、現行制度下での特許の権利化と権利行使について、また、今後予想される変化やそれに対しどのように備えるべきかについてご紹介を致します。
米国では、米国改正特許法(AIA)の施行から丸一年が経過しようとする今もなお、知財の実務家は新しい法律への対応に追われています。また、合衆国最高裁判所や連邦巡回区控訴裁判所(CAFC)の重要な判決によって、これまで知財業界において常識とされていた理解の妥当性が新たに問われています。
このような最近の変化の中には、大西洋を隔てた両地域の制度の調和につながる流れとなるものもありますが、全てがそうではありません。このため、本セミナーでは、欧州および米国におけるこれらの傾向や相違点などについても、それぞれの視点から講演を行います。
実務面で特に関心を集める分野の一つであるライフサイエンスの業界では、変化をみせる法制度の下で大きな挑戦に直面しています。このため、セミナー初日には幅広く一般的なテーマを、そして第二日目にはライフサイエンス関連に焦点をあてたテーマをご紹介致します。セミナーへのお申込みは、ご関心のあるテーマに応じて一日もしくは両日のいずれかが可能となっております。
また、セミナーでは、欧米の比較的見地からのレクチャーに加え、日本の視点からの専門家のコメントも入ります。
なお、両日を通じて講演には日英の同時通訳をご用意しております。また、11月12日には、セミナー後にレセプションディナー（会場：51階六本木ヒルズクラブ）をご用意しております。
多くの皆さまのご参加をお待ちしております。
Subway 地下鉄 Roppongi Station – Hibiya Line Exit 1C (3 min) 日比谷線「六本木駅」1C出口徒歩3分(コンコースにて直結) Azabu-Juban Station – Nanboku Line Exit 4 (12 min) 南北線「麻布十番」4出口徒歩12分 Roppongi Station – O-Edo Line Exit 3 (6 min) 大江戸線「六本木駅」3出口徒歩6分 Azabu-Juban Station – O-Edo Line Exit 7 (9 min) 大江戸線「麻布十番」7出口徒歩9分
Academy Hills
Roppongi Hills Mori Tower 49F6-10-1 Roppongi, Minato-ku, TokyoTel: +81 (0)3-6406-6220
六本木ヒルズ森タワー49階•アカデミーヒルズ〒106-6108東京都港区六本木6-10-1Tel: (03) 6406-6220
www.academyhills.com/aboutus/map.html
contact お問合せ先CPPC Office c/o German Chamber of Commerce and Industry in Japan (Ms. Inui)Sanbancho KS Bldg. 5F, 2-4 Sanbancho, Chiyoda-ku, Tokyo 102-0075, Japan
在日ドイツ商工会議所内 CPPC事務局（担当：乾）〒102-0075 東京都千代田区三番町2-4, 三番町KSビル5FTel: +81 (3) 5276-8826, Fax: +81 (3) 5276-8736 Email: [email protected]
While Europe is finally coming close to introducing both a European
patent with unitary effect throughout the European Union and a Uni-
fied Patent Court, there have been remarkable recent developments
under the present system in all areas of patent law. In this year’s CPPC
seminar, we will look at patent prosecution and litigation under the
present rules as well as the expected changes and how to prepare for
them.
In the U.S., it is approaching almost one full year since the America
Invents Act came into force, and IP practice is still in the course of
adapting to the new law. Moreover, several landmark decisions of the
Supreme Court and the CAFC have called into question what was
common understanding in the IP world for years.
Some, but not all, of the recent changes aim at or lead to harmoniza-
tion between the systems on both sides of the Atlantic, and we will
highlight the differences as well as the trends towards harmonization.
One area of particular interest is the life sciences industries which are
facing big challenges under the changing legal systems. We will there-
fore devote the second seminar day entirely to life science related is-
sues, while the first seminar day will deal with topics of a more gen-
eral nature that will be of interest to all industries. Depending on your
interest, you may register for just one or both seminar days.
In addition to comparative views of the situation in the U.S. and Eu-
rope, expert comments from a Japanese perspective will be provided.
Simultaneous interpretation into Japanese will be provided through-
out both seminars.
On the evening of November 12, all seminar participants are invited to
the CPPC Reception at the Roppongi Hills Club (51st floor).
november 12 (tue): general program8:30 – 9:10 Registration / 受付
9:10 Welcome / 開会のご挨拶
9:20 Navigating ePO Prosecution: A Case Law Update / Patent Prosecution Techniques in the U.S. 欧州特許庁における権利化に関する最近の判例 / 米国におけ る権利化のテクニック
Prosecuting patents before the EPO can sometimes involve surprises.
Recently-identified substantive and procedural issues can sink even a
strong application. We guide you through the latest case law and give
you some simple tips to avoid the problems that many applicants face
in bringing their cases to a safe grant.
For the U.S., we present a review of useful U.S. prosecution tech-
niques including prioritized examination, accelerated design examina-
tion, Patent Prosecution Highway, and interviews.
10:00 Patentability of Software and Business Method Patents ソフトウェアの特許性とビジネスモデル特許
An update on software and business method patents in the U.S. after
the Federal Circuit’s split decision in CLS Bank v. Alice Corp. in May 2013.
We will review this important case, as well as cases leading up to it
and subsequent, to provide guidance on the current state of the law
on business method patents in the U.S.
In Europe, the Technical Boards of Appeal the EPO does allow patents
for software, games and business methods inventions if certain re-
quirements are fulfilled. We will guide you through some illustrative
cases and develop a “tool box” which you can use to easily make your
software etc. inventive and patentable.
10:45 – 11:15 Coffee Break / 休憩
11:15 Recent Case Law on “New Manufacture vs. Repair” 「新製品vsリサイクル品」に関する最近の判例
In many cases, the added value of inventions results from replacing
parts of patented apparatuses during their lifetime. Recent case law
in Europe has given guidance, as to when such replacements can be
covered by patent protection or are to be regarded as admissible re-
pair of a patented item.
As regards the U.S., we will review the definition and scope of the
patent exhaustion doctrine, as well as distinctions between repair and
reconstruction of a patented article
12:00 Product Protection by Process inventions 方法発明による製品保護
According to European patent law, the protection conferred by a pro-
cess claim extends to the product that is directly obtained by the pro-
cess. Recent decisions from the German and UK courts provide guid-
ance on the applicability of this provision for processes that do not
produce three-dimensional objects or chemicals, but generate signals
or information. For the U.S., we will discuss strategies and use of
product-by-process claims, the advantages and disadvantages of such
claims, and the current state of the law in the U.S.
12:45 – 14:00 Lunch / 昼食 (Roppongi Hills Club)
14:00 Update on Licenses and Covenants-Not-to-Sue ライセンスと不争条項に関する最新情報
Licenses and covenants-not-to-sue are often regarded as interchange-
able but they can have different legal implications. We provide an up-
date on the recent case-law in the US and Europe on licenses and
covenants-not-to-sue relating to (i) bankruptcy, (ii) assignments of
the patent, (iii) exhaustion, and (iv) validity challenges. Also, terminat-
ing a license may not free the licensor of all sub licensees; how to
ensure the comprehensive effect of a termination when drafting the
license.
14:45 Litigation Strategies: Recent Trends in europe and the U.S. 訴訟戦略: 欧州と米国における最近の傾向
Recent case law has changed the landscape for patent enforcement in
Europe: Cross-border injunctions have become frequently used in the
Netherlands. New strategies have to be developped for patent enfore-
ment in Germany when negative declaratory actions (so-called “torpe-
does”) have been filed in other countries. Moreover, enforcing stan-
dard-essential patents (SEPs) has become more complex after the RC
Duesseldorf ’s referral to the European Court of Justice.
We will present the U.S. perspective on litigating on multiple fronts.
Discussion of strategies involving review of patents by U.S. Patent Of-
fice through Inter Partes Review (IPR), Covered Business Method
(CBM) Patent Review, and Post Grant Review. Forum shopping and
different standards in U.S. among ITC, Federal Courts, and Patent Of-
fice. Strategies to defend against actions by non-practicing entities
(“patent trolls”).
15:30 – 16:00 Coffee Break / 休憩
16:00 America invents Act After One Year 米国改正特許法から一年
A review of the America Invents Act one year after implemenation.
A general discussion of new rules, procedures, and strategies as well
as feedback on trends after the first year.
16:20 The eU Patent Package 欧州単一特許
The Unified Patent Court Agreement has now been concluded and it
looks as if the Unitary Patent is going to come in Europe, sooner or
later. So it is good time to look at the various complex rules and regu-
lations in more detail.
16:45 Panel Discussion: Do’s and Don’ts in Patent Prosecution and Litigation / Q&A パネルディスカッション / Q&A
In this session we will address your questions and invite all speakers
to highlight what is most important in their view to be successful
before the various courts and patent offices. We will also present an
outlook to expected changes.
17:45 Closing Remark / 閉会のご挨拶
18:00 – 20:30 Reception Dinner / レセプション (Roppongi Hills Club)
在日ドイツ商工会議所内 CPPC事務局（担当：乾）〒102-0075 東京都千代田区三番町2-4, 三番町KSビル5FTel: +81 (3) 5276-8826, Fax: +81 (3) 5276-8736 Email: [email protected]
november 13 (wed): life science special8:30 – 9:00 Registration / 受付
9:00 Welcome / 開会のご挨拶
9:05 Recent U.S. cases and ePO Appeal Board Practice in the Life Sciences ライフサイエンス分野における最近の米国の判例とePO審 判部の実務
Review of recent cases including Mayo v. Prometheus (method for de-
termining dosages) and Myriad Genetics (human genes) and how
these cases are affecting patent strategies for life sciences companies.
At the EPO, there are currently 27 Technical Boards of Appeal, 7 of
which handle life science cases. Upon reviewing 585 decisions of these
boards, the lecture tries to identify common trends and differences
between the boards.
9:45 Case Law Update on Supplementary Protection Certificates SPCに関する最近の判例
Over the last 2 years, very important decisions have come up which
have a strong influence on the practice for filing SPC applications and
for obtaining protection by SPCs. The consequences resulting from the
court decisions will be discussed in more detail together with open
questions still to be decided by case law.
10:10 Recent Developments in PTA Calculations PTAの算出に関する最近の展開
Patent Term Adjustment (PTA) is a hot topic in the U.S. and we will
review the AIA Technical Corrections Act and the Exelixis cases.
10:30 – 11:00 Coffee Break / 休憩
11:00 enablement and Written Description Requirement with respect to U.S. Life Sciences Applications 米国でのライフサイエンス特許出願における実施可能要件 と記述要件
A review of 35 U.S.C. 112 enablement and written description issues as
they affect bio-based inventions, including methods of treatment.
11:20 experimental data for new therapeutic indications – How much must be in the application? 新しい治療適応への実験データをどこまで出願に含めるべきか?
Applicants understandably want to file their applications as early as
possible. On the other hand, too speculative patent applications with
no data support run the risk of being rejected by the EPO. A new EPO
appeal board decision casts some hope for applicants facing this di-
lemma.
11:40 Therapeutic use versus non-therapeutic use 治療上の使用と非治療的使用
When an invention refers to a treatment of the human or animal
body, problems can come up when the therapeutic aspect and the
non- therapeutic aspect of this treatment can not be clearly limited
against each other. These problems will be discussed in more detail,
and also possibilities will be shown to overcome them and to result in
the grant of respective patents.
12:10 – 13:15 Lunch / 昼食 (Roppongi Hills Club)
13:15 Pharmaceutical Patents and Antitrust Law in Prosecution, enforcement and Settlement 医薬特許と権利化・権利行使・和解における独占禁止法上の 留意点
On both sides of the Atlantic antitrust authorities and courts have
shown a heightened interest in the enforcement of antitrust law in
the pharmaceutical field. (1) Pay-for-delay: In June 2013, the U.S. Su-
preme Court, in FTC v. Actavis found that pay-for-delay settlements
may violate antitrust laws. The European Commission fined Lundbeck
and several companies marketing generic medicines € 146 Million for
agreeing on a delayed market entry. Settlement options in view of
these cases will be discussed. (2) In AstraZeneca the European Court
of Justice confirmed that providing wrong information to a patent of-
fice may be a violation of antitrust law.
14:00 effective enforcement of pharma patents 医薬特許の効果的な行使
Cross-border injunctions in Europe are available and very useful
against infringers distributing pharmaceutical products throughout
Europe. However, in most cases patents still have to be enforced
country-by-country. Recent case law shows which countries are pat-
entee-friendly when time is of the essence and provisional measures
are required to enforce pharma patents effectively.
As regards the U.S., we will discuss friendly/nonfriendly and fast/slow
venues in the United States.
14:45 – 15:15 Coffee Break / 休憩
15:15 Binding advice on antibody inventions 抗体の発明に関するアドバイス
The criteria used for determining the patentability of inventions relat-
ing to antibodies is constantly changing due to the rapid develop-
ments in this technical field. An overview of possible structural as well
as functional features that can be used to define antibody inventions
and formulate antibody claims is provided.
16:00 Human embryonic stem cells ヒトeS細胞
This interesting and politically controversial technical field has seen
decisive case law in the last year. We will assess both EU and German
decisions and explore their impact on the patentability practice in this
area at the EPO. How does it affect already pending and future ap-
plications?
A discussion of the impact of the Myriad case on patentability of iso-
lated stem cells in the U.S. and a review of following cases such as the
recently filed complaint against Wisconsin Alumni Research Founda-
tion (WARF) by public interest groups.
16:45 Panel Discussion: Do’s and Don’ts in Life Science iP Prosecution and Litigation / Q&A パネルディスカッション / Q&A
Focussing on the topics addressed on the second day of the confer-
ence, we will address your questions and invite all speakers to high-
light what is most important in their view to be successful in prosecu-
tion and litigation of life science patents in Europe and the US.
17:15 end of Conference / 閉会
simultaneous translation 同時通訳: Yumiko Hayashi · 林由美子 / Keiko Mihara · 三原恵子 / Junji Tomoda · 友田淳治
speakers 講師
Dr. Matthias KindlerDr. マティアス・キンドラー
Partner & Co-head of Chemical Department, Hoffmann ·
Eitle, Munich
Dr. rer. nat. (Chemistry), European and German Patent
Attorney
Specialized in chemical and pharmaceutical patents, in particular
prosecution, opposition and appeal proceedings before the EPO,
invalidation actions and infringement litigations
Numerous cases in SPC matters before the German Federal Patent
Court, the German Supreme Court and the European Court of Justice
Dr. Mark A G JonesDr. マーク・ジョーンズ
Associate, Mechanical Engineering Department,
Hoffmann · Eitle, London
DPhil (Physics) (Oxford University), European and
Chartered British Patent Attorney
Particular interests in applied physics, high-tech manufacturing
and medical technology
Legal opinions and advisory services with regard to both European
and British law and practice
Contentious and non-contentious matters before the European
and British Patent Offices
Steven G. Davis, Ph.D.スティーブン・デイビス
Partner, IP/IT Group, McCarter & English LLP
(Boston, MA)
J.D., Case Western University School of Law; Ph.D., John
Hopkins University, Chemistry; M.S., John Hopkins
University; B.A., Swarthmore College
Specializes in chemical and pharmaceutical patents
Advises clients on general portfolio strategy, freedom to operate
issues, due diligence investigations and licensing issues
Dr. Thorsten BauschDr. トーステン・バウシュ
Partner & Co-head of Chemical Dept.,
Hoffmann · Eitle, Munich
Dr. rer. nat. (Chemistry), Dipl.-Chem., European
and German Patent Attorney
Specialized in chemical, pharmaceutical and biotech patents, in
particular litigation, both cross-border and national
Frequently involved in cases before the EPO, the German Federal
Patent Court, the German Supreme Court and the European Court
of Justice
Michael R. Frisciaマイケル・フリシャ
Partner, IP/IT Group, McCarter & English LLP
(Newark, NJ)
Bachelor of Engineering, Stevens Institute of Technology;
J.D. New York Law School
Specializes in patent prosecution in mechanical and
electrical arts
Extensive IP litigation experience; Inter Partes
Reexamination / Review; Mediation
Adjunct Professor, Seton Hall Law School 1999 – 2006
Dr. Thomas KochDr. トーマス・コッホ
Partner, Electrical & IT Department, Hoffmann · Eitle,
Munich
PhD of University College London, UK; European
and German Patent Attorney
Work experience at Siemens Research Labs Munich,
Germany & University College London, UK / assistant professor at King’s
College London in Optical communications & Microwave Technology
Specialized in prosecution, opposition and litigation, in particular in
telecommunications, computer software, semiconductors, digital
communications (e.g. MP3) & business patents
Mark D. Giarratanaマーク・ジラターナ
Partner, IP/IT Group, McCarter & English LLP
(Hartford, CT)
Admitted in New York, Connecticut, and to U.S.
Patent and Trademark Office
J.D., University of Connecticut School of Law, with
honors; B.S.M.E., Catholic University
Extensive experience in litigating patent and other IP cases
in federal courts
Advises clients on IP issues related to all aspects of patent,
trademark and copyright procurement, litigation, licensing, and
the negotiation of IP transactions
Thomas O. Hooverトーマス・フーバー
Partner, IP/IT Group, McCarter & English, LLP
(Boston, MA)
J.D., South Texas College of Law; A.B., Worcester
Polytechnic Institute and College of the Holy Cross
His practice includes the prosecution of patents before USPTO,
patent appeals, reissue, re-examination and opposition proceedings
in foreign jurisdictions
Has served as lead counsel in contested interference proceedings and
conducted trade secret and patent infringement litigation
Gerald Levyジェラルド・レヴィー
Partner, IP/IT Group, McCarter & English, LLP
(New York, NY)
J.D. Brooklyn Law School; B.S.M.E Columbia University
Admitted in New York and U.S. Patent & Trademark
Office
Patent professional experienced in patent prosecution, licensing,
strategic planning and litigation
Extensive experience in handling various patent office matters including
complex re-examinations and interferences
Christopher Furlongクリストファー・フォーロング
Partner, Mechanical Department, Hoffmann · Eitle,
Munich
B.E., Mech. Eng, Univ. Coll. Dublin
European Patent Attorney (1994), Cert. In IP Law,
Univ. of London (1995), Chartered British Patent
Attorney (2002)
Frequent speaker on issues of European IP law
Specialised in European prosecution and inter partes validy
and infringement proceedings
speakers 講師
Dr. Nadja G. MunckeDr. ナディア・ムンケ
Associate, Biotech Department, Hoffmann · Eitle,
Munich
Dr. rer. nat. (Biology), European and Chartered British
patent attorney
Examination, opposition and appeal proceedings
before the EPO
Legal Opinions and strategy advice
Particular expertise in the area of cancer/diabetes/Alzheimer’s disease,
antibodies, vaccines, cell culture, etc.
Dr. Joachim RenkenDr. ヨアヒム・レンケン
Partner, Biotech Department, Hoffmann · Eitle, Munich
Dr. rer. nat. (Biophysical Chemistry), European and
German Patent Attorney
Specialized in biotech, chemical, and pharmaceutical
patents, in particular examination, opposition and
appeal proceedings before the EPO, invalidation actions, and
infringement actions
Frequent lecturer on issues of European patent law
Dr. Clemens Tobias SteinsDr. クレメンス トビアス・シュタインス
Dr. jur., Legal Department, Hoffmann Eitle, Munich
Attorney at law since 1999
Specialized in IP contracts and transactional work,
patent litigation
Several years work experience at a law firm in Tokyo
and counseling Japanese entities on European law
Keith J. McWhaキース・マクワ
Partner, IP/IT Group, McCarter & English, LLP
(Newark, NJ & New York, NY)
J.D., Seton Hall University School of Law; M.S.,
University of Massachusetts; B.S., University of
Massachusetts summa cum laude
Extensive experience in IP prosecution, opinions, transaction matters,
due diligence and client counseling
Holger Stratmann ホルガー・シュトラトマン
Partner & Co-head of Legal Department,
Hoffmann · Eitle, Munich
Postgraduate Diploma in EU Competition Law from
King‘s College London (1996)
Specialised in national and cross-border patent and unfair
competition litigation, licensing and contract law, anti-counterfeiting
and product piracy, coordination of EU-wide border seizure proceedings
Publications and lectures on patent law, domain grabbing
and product piracy
Prof. Katsuya Tamai 玉井克哉 教授 東京大学先端科学技術研究センター教授（知的財産法）マックス・プランク国際知的財産法研究所客員研究員(1989 – 92)
ジョージ・ワシントン大学ロー・スクール及び連邦巡回区担当合衆国控訴裁判所客員研究員(1999 – 2000)
慶應義塾大学特別招聘教授政策研究大学院大学客員教授
Dr. Joe Taormino Dr. ジョー・タオルミノ
Partner & Co-head of the Biotech Department,
Hoffmann · Eitle, Munich
Ph. D. (The John Hopkins University), molecular
biologist, Doctoral thesis in the field of biochemistry,
cellular and molecular biology and genetics.
European Patent Attorney since 1998
Specialized in biotech patents, litigation and all aspects of prosecution
procedures before the EPO
Various lectures and publications on Biotech and Intellectual Property
Dr. Henrik Vocke Dr. ヘンリック・フォッケ
Partner, Mechanical Department, Hoffmann · Eitle,
Munich
Dr.-Ing. (Civ. Eng.) of University of Stuttgart, European
and German Patent Attorney
Working experience in Japan (Kajima Technical Research
Institute, Tokyo)
Specialized in prosecution and litigation, in particular in developing and
enforcing combined patent and utility model strategies
Frequent speaker on issues of European and German IP law
Maria Laccotripe Zacharakis, Ph.D. マリア・ラコトライプ・ザカラキス
Partner, IP/IT Group, McCarter & English, LLP
(Boston, MA)
J.D., Suffolk University Law School, High Technology Law
Concentration with Distinction; Ph.D., Boston University
of Medicine, Biochemistry; B.A./M.A., Boston University, Biology/
Biotechnology, magna cum laude
Extensive experience in patent preparation and prosecution, due
diligence evaluations of patent portfolios, freedom-to-operate
assessments, patent validity opinions and competitive landscape
analyses
Specializes in the area of life sciences/biotechnology
Dr. Dirk Schüssler-Langeheine Dr. ディルク・シュスラー＝ランゲハイネ
Dr. jur., Partner & Co-head of Legal Department,
Hoffmann · Eitle, Munich
Attorney-at-Law (since 2000)
Specialised in national and multi-jurisdictional patent
litigation, licensing, competition law, contract law and arbitration
Fluent in Japanese, Doctoral thesis on Japanese law on damages (2004)
Publications and lectures on German, European and Japanese IP Law
